Immune Response in Melanoma: A Basis to Understand the Role of Immunotherapy with Immune Checkpoint Inhibitors

Immune Response in Melanoma: A Basis to Understand the Role of Immunotherapy with Immune Checkpoint Inhibitors

The knowledge of the pathophysiology of tumour progression is crucial to understand the therapeutic targets in order to control the disease. The mechanisms used by the immune system to affect cancer development and progression has been a challenging question in immunology. It is now postulated that...

Full description

Bibliographic Details
Main Authors:	Eugénia Matos Pires, Cecília Moura
Format:	Article
Language:	English
Published:	Sociedade Portuguesa de Dermatologia e Venereologia 2018-04-01
Series:	Revista da Sociedade Portuguesa de Dermatologia e Venereologia
Subjects:	Immunologic Surveillance Immunotherapy Melanoma/immunology Melanoma/therapy Programmed Cell Death 1 Receptor
Online Access:	https://revista.spdv.com.pt/index.php/spdv/article/view/868

Similar Items

Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy
by: Robin Reschke, et al.
Published: (2021-07-01)

Genetic Variants in Immune Related Genes as Predictors of Responsiveness to BCG Immunotherapy in Metastatic Melanoma Patients
by: Romela Irene Ramos, et al.
Published: (2021-12-01)

Soluble immune checkpoints and T-cell subsets in blood as biomarkers for resistance to immunotherapy in melanoma patients
by: Devayani Machiraju, et al.
Published: (2021-01-01)

Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review
by: Qingyue Zheng, et al.
Published: (2020-12-01)

Is There a Place for Immune Checkpoint Inhibitors in Vulvar Neoplasms? A State of the Art Review
by: Fulvio Borella, et al.
Published: (2021-12-01)

Combining targeted therapy and immune checkpoint inhibitors in the treatment of metastatic melanoma
by: Teresa Kim, et al.
Published: (2014-12-01)

Baseline antibody profiles predict toxicity in melanoma patients treated with immune checkpoint inhibitors
by: Michael F. Gowen, et al.
Published: (2018-04-01)

Modern Aspects of Immunotherapy with Checkpoint Inhibitors in Melanoma
by: Vera Petrova, et al.
Published: (2020-03-01)

Biological Factors behind Melanoma Response to Immune Checkpoint Inhibitors
by: Magdalena Olbryt, et al.
Published: (2020-06-01)

Immune signature as predictive marker for response to checkpoint inhibitor immunotherapy and overall survival in melanoma
by: Franziska K. Krebs, et al.
Published: (2021-03-01)

Targeted Alpha-Particle Radiotherapy and Immune Checkpoint Inhibitors Induces Cooperative Inhibition on Tumor Growth of Malignant Melanoma
by: Mengshi Li, et al.
Published: (2021-07-01)

Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan
by: Chiao-En Wu, et al.
Published: (2020-06-01)

Real-World Impact of Immune Checkpoint Inhibitors in Metastatic Uveal Melanoma
by: Kalijn Fredrike Bol, et al.
Published: (2019-10-01)

No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study
by: Michele Guida, et al.
Published: (2021-01-01)

The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients
by: Katarzyna Tomela, et al.
Published: (2020-09-01)

Current Status and Prospects of Immunotherapy for Gynecologic Melanoma
by: Mayuka Anko, et al.
Published: (2021-05-01)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
by: Shigehisa Kitano, et al.
Published: (2018-07-01)

Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update
by: Sonja Vukadin, et al.
Published: (2021-07-01)

Immune biomarkers for prognosis and prediction of responses to immune checkpoint blockade in cutaneous melanoma
by: Nicolas Jacquelot, et al.
Published: (2017-08-01)

Frequency, Treatment and Outcome of Immune-Related Toxicities in Patients with Immune-Checkpoint Inhibitors for Advanced Melanoma: Results from an Institutional Database Analysis
by: Florentia Dimitriou, et al.
Published: (2021-06-01)

Programmed cell death 1 checkpoint inhibitors in the treatment of patients with advanced melanoma
by: Jacek Mackiewicz, et al.
Published: (2017-03-01)

CANCER IMMUNOTHERAPY BASED ON THE BLOCKADE OF IMMUNE CHECKPOINTS
by: A. V. Bogolyubova, et al.
Published: (2015-10-01)

Immune co-culture cell microarray – a feasible tool for high-throughput functional investigation of lymphocyte–cancer interactions
by: Erez Nissim Baruch, et al.
Published: (2020-01-01)

The clinically relevant role tregs play in establishing an immunosuppressive tumor microenvironment in melanoma
by: Habib, Corey
Published: (2019)

Immune Checkpoint-Mediated Interactions Between Cancer and Immune Cells in Prostate Adenocarcinoma and Melanoma
by: Angela Rita Elia, et al.
Published: (2018-07-01)

Checkpoint inhibition immunotherapy for advanced local and systemic conjunctival melanoma: a clinical case series
by: Paul T. Finger, et al.
Published: (2019-03-01)

Immune Checkpoint Inhibitors New Insights and Recent Progress
Published: (2023)

Cutaneous Adverse Events of Targeted Therapies and Immune-Checkpoint Inhibitors in Patients with Melanoma
by: Rita Pimenta, et al.
Published: (2021-04-01)

Immune Checkpoint Inhibitors in Melanoma: Review and Update
by: Eugénia Matos Pires, et al.
Published: (2018-10-01)

Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma
by: Duaa O. Khair, et al.
Published: (2019-03-01)

Triple threat to cancer: rationale for combining oncolytic viruses, MEK inhibitors, and immune checkpoint blockade
by: Praveen K. Bommareddy, et al.
Published: (2019-04-01)

Patients with melanoma of unknown primary show better outcome under immune checkpoint inhibitor therapy than patients with known primary: preliminary results
by: Thilo Gambichler, et al.
Published: (2019-12-01)

Characterization of genetics in patients with mucosal melanoma treated with immune checkpoint blockade
by: Elizabeth I. Buchbinder, et al.
Published: (2021-04-01)

Identification of subtypes correlated with tumor immunity and immunotherapy in cutaneous melanoma
by: Qian Liu, et al.
Published: (2021-01-01)

Response and survival of metastatic melanoma patients treated with immune checkpoint inhibition for recurrent disease on adjuvant dendritic cell vaccination
by: Wouter W. van Willigen, et al.
Published: (2020-01-01)

Antibiotics are associated with decreased progression-free survival of advanced melanoma patients treated with immune checkpoint inhibitors
by: Arielle Elkrief, et al.
Published: (2019-04-01)

The Role of Immune Checkpoint Blockade in Uveal Melanoma
by: Anja Wessely, et al.
Published: (2020-01-01)

Tumor immunogenomic signatures improve a prognostic model of melanoma survival
by: Leah Morales, et al.
Published: (2021-02-01)

Targeting regulatory T cells for immunotherapy in melanoma
by: Lili Huang, et al.
Published: (2021-04-01)

Checkpoint inhibitors for malignant melanoma: a systematic review and meta-analysis
by: Karlsson AK, et al.
Published: (2017-08-01)